2024-03-29T00:30:14Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/48022023-11-22T12:26:58Zcom_20.500.12105_2053com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2054
00925njm 22002777a 4500
dc
Pajares, Bella
author
Pollan-Santamaria, Marina
author
Martín, Miguel
author
Mackey, John R
author
Lluch, Ana
author
Gavila, Joaquín
author
Vogel, Charles
author
Ruiz-Borrego, Manuel
author
Calvo, Lourdes
author
Pienkowski, Tadeusz
author
Rodríguez-Lescure, Álvaro
author
Seguí, Miguel Angel
author
Tredan, Olivier
author
Antón, Antonio
author
Ramos, Manuel
author
Cámara, María del Carmen
author
Rodríguez-Martín, César
author
Carrasco, Eva
author
Alba, Emilio
author
2013-11-06
Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification.
METHODS:
We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003-02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences of such prognostic effects by subtype.
RESULTS:
Multivariate survival analyses adjusting for age, tumor size, nodal status, menopausal status, surgery type, histological grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, chemotherapy regimen, and under-treatment showed that obese patients (BMI 30.0 to 34.9) had similar prognoses to that of patients with a BMI < 25 (reference group) in terms of recurrence (Hazard Ratio [HR] = 1.08, 95% Confidence Interval [CI] = 0.90 to 1.30), BCM (HR = 1.02, 0.81 to 1.29), and OM (HR = 0.97, 0.78 to 1.19). Patients with severe obesity (BMI ≥ 35) had a significantly increased risk of recurrence (HR = 1.26, 1.00 to 1.59, P = 0.048), BCM (HR = 1.32, 1.00 to 1.74, P = 0.050), and OM (HR = 1.35, 1.06 to 1.71, P = 0.016) compared to our reference group. The prognostic effect of severe obesity did not vary by subtype.
CONCLUSIONS:
Severely obese patients treated with anthracyclines and taxanes present a worse prognosis regarding recurrence, BCM, and OM than patients with BMI < 25. The magnitude of the harmful effect of BMI on survival-related outcomes was similar across subtypes.
Breast Cancer Res. 2013; 15(6): R105
http://hdl.handle.net/20.500.12105/4802
24192331
10.1186/bcr3572
1465-542X
Breast Cancer Research
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis